{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T04:54:35Z","timestamp":1774241675833,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.vaccine.2021.03.012","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T04:43:20Z","timestamp":1616042600000},"page":"2088-2093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and immunogenicity of inactivated hepatitis-A vaccine developed by Human Biologicals Institute in two age groups of healthy subjects: A phase I open label study"],"prefix":"10.1016","volume":"39","author":[{"given":"Sai Krishna","family":"Susarla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonali","family":"Palkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pardha Saradhi","family":"SV","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arundhati","family":"Diwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supriya","family":"Barsode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Satish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BC","family":"Rajashakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Sandhya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajendra","family":"Lingala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devi Prasad","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.03.012_b0005","unstructured":"Hepatitis A Fact Sheet, WHO, Updated 9 July 2019.https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-a (accessed on 10th September 2019)."},{"key":"10.1016\/j.vaccine.2021.03.012_b0010","unstructured":"WHO position paper on hepatitis A vaccines \u2013 June 2012. Weekly Epidemiological Record, 13 July 2012; 87 (28\/29): 261\u201376."},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.012_b0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1128\/CMR.14.1.38-58.2001","article-title":"Hepatitis A: old and new","volume":"14","author":"Cuthbert","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2021.03.012_b0020","doi-asserted-by":"crossref","unstructured":"Elisabetta Franco, Cristina Meleleo, Laura Serino, Debora Sorbara, Laura Zaratti. Hepatitis A: Epidemiology and prevention in developing countries. World J Hepatol; 2012;4(3):68\u201373.","DOI":"10.4254\/wjh.v4.i3.68"},{"key":"10.1016\/j.vaccine.2021.03.012_b0025","unstructured":"Public health control of hepatitis A: Memorandum from a WHO meeting. Bulletin of World Health Organization; 1995;73(1):15\u201320. http:\/\/apps.who.int\/iris\/bitstream\/10665\/48843\/1\/bulletin_1995_73(1)_15-20.pdf, (accessed on 10th September 2019)."},{"key":"10.1016\/j.vaccine.2021.03.012_b0030","unstructured":"National Action Plan Combating Viral Hepatitis in India, 2019. National Health Mission, Ministry of Health and Family Welfare, Government of India; Introduction, Section \u2013 I: Magnitude of the problem and high risk areas\/groups; p-23."},{"key":"10.1016\/j.vaccine.2021.03.012_b0035","doi-asserted-by":"crossref","unstructured":"Ramesh Verma and Pardeep Khanna. Hepatitis A vaccine should receive priority in National Immunization Schedule in India. Human Vaccines Immunotherapeut; 2012;8(8):1132\u20131134.","DOI":"10.4161\/hv.20475"},{"key":"10.1016\/j.vaccine.2021.03.012_b0040","doi-asserted-by":"crossref","unstructured":"Jelinek Tomas, Nothdurft Hans D. Changing epidemiology of hepatitis a: time for vaccination in childhood. J Travel Med; 7(3): 142\u20138.","DOI":"10.2310\/7060.2000.00046"},{"issue":"43","key":"10.1016\/j.vaccine.2021.03.012_b0045","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.15585\/mmwr.mm6743a5","article-title":"Update: recommendations of the advisory committee on immunization practices for use of Hepatitis A vaccine for postexposure prophylaxis and for preexposure prophylaxis for international travel","volume":"67","author":"Nelson","year":"2018","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2021.03.012_b0050","doi-asserted-by":"crossref","unstructured":"Vidya Arankalle, Monjori Mitra, Sheila Bhave, Apurba Ghosh, Sundaram Balasubramanian, Suparna Chatterjee et al. Changing Epidemiology of Hepatitis A virus in Indian children. Vaccine: Development and Therapy; 2014;(4):7\u201313.","DOI":"10.2147\/VDT.S53324"},{"key":"10.1016\/j.vaccine.2021.03.012_b0055","doi-asserted-by":"crossref","unstructured":"Manoj V. Murhekar, M. Ashok, K. Kanagasabai, Vasna Joshua, M. Ravi, R. Sabarinathan et al. Epidemiology of hepatitis A and hepatitis E based on laboratory surveillance data\u2014India, 2014\u20132017. Am. J. Trop. Med. Hyg. 99(4) 2018:1058-61.","DOI":"10.4269\/ajtmh.18-0232"},{"issue":"3","key":"10.1016\/j.vaccine.2021.03.012_b0060","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.mjafi.2016.06.011","article-title":"Viral Hepatitis: Indian Scenario","volume":"72","author":"Satsangi","year":"2016","journal-title":"Med J Armed Forces India."},{"key":"10.1016\/j.vaccine.2021.03.012_b0065","doi-asserted-by":"crossref","unstructured":"Gripenberg M, Aloysia D\u2019Cor N, L\u2019Azou M, Marsh G, Druelles S, Nealon J. Changing Sero-Epidemiology of Hepatitis A in Asia Pacific Countries: A Systematic Review. Int J Infect Diseases 68(2018):13\u20137.","DOI":"10.1016\/j.ijid.2017.12.021"},{"key":"10.1016\/j.vaccine.2021.03.012_b0070","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1017\/S0950268804002857","article-title":"Declining Hepatitis A seroprevalence: a global review and analysis","volume":"132","author":"Jacobsen","year":"2004","journal-title":"Epidemiol. Infect."},{"issue":"2","key":"10.1016\/j.vaccine.2021.03.012_b0075","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4103\/0255-0857.180354","article-title":"An outbreak of hepatitis A virus among children in a flood rescue camp: a post-disaster catastrophe","volume":"34","author":"Pal","year":"2016","journal-title":"Ind J Med Microbiol"},{"key":"10.1016\/j.vaccine.2021.03.012_b0080","doi-asserted-by":"crossref","unstructured":"Rakesh PS, Carmel Regeela Mainu TT, Raj A, Babu D, Rajiv M et al., 2018. Investigating a community wide outbreak of hepatitis A in Kerala, India. J Family Med Prim Care, 2018;7(6):1537\u201341.","DOI":"10.4103\/jfmpc.jfmpc_127_18"},{"key":"10.1016\/j.vaccine.2021.03.012_b0085","doi-asserted-by":"crossref","unstructured":"Srinivasan M, Natarajan Sindhu K, Kumar SJ, Abraham P, Anandan S, Balaji V et al. Hepatitis A outbreak with the concurrence of Salmonella typhi and Salmonella poona infection in children of urban Vellore, South India. The Am J Trop Med Hyg; 102(6):2020:1249-52.","DOI":"10.4269\/ajtmh.19-0742"},{"key":"10.1016\/j.vaccine.2021.03.012_b0090","first-page":"699","article-title":"Epidemiological transition of hepatitis A in India: Issues for vaccination in developing countries","volume":"128","author":"Mathur","year":"2008","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.vaccine.2021.03.012_b0095","doi-asserted-by":"crossref","unstructured":"Van Damme Pierre, Thoelen Stefan, Cramm Myrjam, Meheus Andr\u00e9. Safety and immunogenicity of a high\u2013potency inactivated Hepatitis A vaccine. J Travel Med; 3(2);1996:83\u201390.","DOI":"10.1111\/j.1708-8305.1996.tb00711.x"},{"issue":"7","key":"10.1016\/j.vaccine.2021.03.012_b0100","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1080\/21645515.2015.1045167","article-title":"A retrospective pooled analysis assessing the effect of age on the immunogenicity of Havrix\u2122 in healthy adults","volume":"11","author":"Van Der Meeren","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.03.012_b0105","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/01.TA.0000162148.03280.02","article-title":"Tetanus and trauma: a review and recommendations","volume":"58","author":"Rhee","year":"2005","journal-title":"J Trauma"},{"key":"10.1016\/j.vaccine.2021.03.012_b0110","unstructured":"Guidance for Industry; Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials - U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research - September 2007."},{"key":"10.1016\/j.vaccine.2021.03.012_b0115","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) - Version 4.0; Published: May 28, 2009 (v4.03: June 14, 2010); U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21002802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21002802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:55:14Z","timestamp":1759402514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21002802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":23,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0264410X21002802"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.03.012","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of inactivated hepatitis-A vaccine developed by Human Biologicals Institute in two age groups of healthy subjects: A phase I open label study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}